OXFORD, England, April 21 /CNW/ - Circassia Ltd, a specialty
biopharmaceutical company focused on allergy, announced today that it has
initiated a phase II clinical study of its ToleroMune(R) technology in allergy
patients with asthma. The trial builds on positive phase II results that
demonstrated the potential clinical benefits of ToleroMune allergy therapy,
and extends clinical investigations to those with allergy-associated asthma.
The latest study, which is underway in Canada, will enrol 48 patients
with confirmed cat allergies and cat-allergen induced asthma. The randomised,
double-blind, placebo-controlled trial will study the use of a standard dose
of ToleroMune administered over a number of weeks. This is in marked contrast
to most current immunotherapy treatments, which require carefully escalated
weekly dosing over many months, followed by further monthly doses for several
years, to reduce the risk of potentially serious adverse reactions. During the
study, each patient will receive a controlled 'challenge' with cat allergens,
both before and after treatment, to allow investigators to assess the effect
of ToleroMune therapy compared to placebo.
"This study marks an important milestone in the development of our
ToleroMune anti-allergy technology, as it extends our target patient group to
those with more serious allergies that can result in asthma attacks," said
Steve Harris, Circassia's CEO. "We believe that Circassia's allergy therapies
will offer patients important clinical benefits. Most existing treatments
address either symptoms only, or require lengthy and complicated dosing
because of their potential to lead to serious and even lifethreatening
reactions. In contrast, our clinical results show that ToleroMune has the
potential to treat the underlying causes of allergies, using short and simple
courses of treatment that minimize the risk of severe side effects."
Circassia is a specialty biopharmaceutical company focused on the field
of allergy. The company's range of allergy therapeutics utilizes its
proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's
anti-allergy products offer potential major clinical benefits compared with
existing therapies, and consequently have significant market opportunities.
Over 150 million people suffer from allergic rhinitis in the US and Europe,
and the market for current treatments is approximately $12 billion per year.
The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly
10% of Europeans suffering from the condition.
ToleroMune technology has additional potential regulatory and supply
benefits for Circassia. Its state-of-the-art manufacturing fits with changes
in the European regulatory environment, where authorities are increasingly
treating allergen immunotherapies as pharmaceutical products, and eliminating
the batch-to-batch potency variability that is an intrinsic feature of many
Circassia has a highly experienced management team with a proven track
record in product development and commercialization. Having successfully
completed two fundraising rounds the company is backed by a syndicate of
world-class venture capital and institutional investors, including Imperial
Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.
For more information please visit http://www.circassia.co.uk.
For further information:
For further information: Steve Harris, CEO, Circassia, Tel:
+44-(0)1865-784574; Rob Budge, RJB Communications, Tel: +44-(0)1865-760969,